MicroRNAs in Cardiovascular Disease

Journal of the American College of Cardiology

Volumn 68, Issue 23, 2016, Pages 2577-2584

  Barwari, Temo ^a   Joshi, Abhishek ^a   Mayr, Manuel ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

biomarkers; genetic therapy; noncoding RNA; RNA therapeutic

Indexed keywords

DOUBLE STRANDED RNA; MESSENGER RNA; MICRORNA; MICRORNA 122; MICRORNA 126; MICRORNA 133; MICRORNA 223; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR GENE THERAPY; DISEASE MARKER; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HEART ELECTROPHYSIOLOGY; HEART MUSCLE FIBROSIS; HUMAN; HUMAN GENOME; HYPERTROPHIC CARDIOMYOPATHY; LIPID METABOLISM; MEDICAL RESEARCH; METHODOLOGY; MOLECULAR GENETICS; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; REVIEW; RISK REDUCTION; RNA ANALYSIS; RNA BINDING; RNA SEQUENCE; TISSUE REGENERATION; BIOSYNTHESIS; GENETICS; METABOLISM;

BIOMARKERS; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS;

EID: 85002795216     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.09.945     Document Type: Review

References (80)

1. 1 Venter, J.C., Adams, M.D., Myers, E.W., et al. The sequence of the human genome. Science 291 (2001), 1304–1351.
2. 2 Lee, R.C., Feinbaum, R.L., Ambros, V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75 (1993), 843–854.
3. 3 Condorelli, G., Latronico, M.V.G., Cavarretta, E., microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol 63 (2014), 2177–2187.
4. 4 Ipsaro, J.J., Joshua-Tor, L., From guide to target: molecular insights into eukaryotic RNA-interference machinery. Nat Struct Mol Biol 22 (2015), 20–28.
5. 5 Jonas, S., Izaurralde, E., Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 16 (2015), 421–433.
6. 6 Bang, C., Batkai, S., Dangwal, S., et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 124 (2014), 2136–2146.
7. 7 Zampetaki, A., Mayr, M., MicroRNAs in vascular and metabolic disease. Circ Res 110 (2012), 508–522.
8. 8 Pritchard, C.C., Cheng, H.H., Tewari, M., MicroRNA profiling: approaches and considerations. Nat Rev Genet 13 (2012), 358–369.
9. 9 Wang, Z., Gerstein, M., Snyder, M., RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10 (2009), 57–63.
10. 10 van Rooij, E., Olson, E.N., MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 11 (2012), 860–872.
11. 11 Ganesan, J., Ramanujam, D., Sassi, Y., et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127 (2013), 2097–2106.
12. 12 Borel, F., Kay, M.A., Mueller, C., Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther 22 (2014), 692–701.
13. 13 Krützfeldt, J., Rajewsky, N., Braich, R., et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438 (2005), 685–689.
14. 14 Janssen, H.L.A., Reesink, H.W., Lawitz, E.J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 368 (2013), 1685–1694.
15. 15 Gomez, I.G., MacKenna, D.A., Johnson, B.G., et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 125 (2015), 141–156.
16. 16 Dalpke, A., Helm, M., RNA mediated Toll-like receptor stimulation in health and disease. RNA Biol 9 (2012), 828–842.
17. 17 Carè, A., Catalucci, D., Felicetti, F., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13 (2007), 613–618.
18. 18 Castaldi, A., Zaglia, T., Di Mauro, V., et al. MicroRNA-133 modulates the β1-adrenergic receptor transduction cascade. Circ Res 115 (2014), 273–283.
19. 19 Trajkovski, M., Ahmed, K., Esau, C.C., et al. MyomiR-133 regulates brown fat differentiation through Prdm16. Nat Cell Biol 14 (2012), 1330–1335.
20. 20 Matkovich, S.J., Wang, W., Tu, Y., et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 106 (2010), 166–175.
21. 21 Elia, L., Contu, R., Quintavalle, M., et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 120 (2009), 2377–2385.
22. 22 Yang, B., Lin, H., Xiao, J., et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13 (2007), 486–491.
23. 23 Zhao, Y., Ransom, J.F., Li, A., et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129 (2007), 303–317.
24. 24 Karakikes, I., Chaanine, A.H., Kang, S., et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc, 2, 2013, e000078.
25. 25 Krenz, M., Robbins, J., Impact of beta-myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol 44 (2004), 2390–2397.
26. 26 van Rooij, E., Sutherland, L.B., Qi, X., et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316 (2007), 575–579.
27. 27 Montgomery, R.L., Hullinger, T.G., Semus, H.M., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124 (2011), 1537–1547.
28. 28 Kakimoto, Y., Tanaka, M., Kamiguchi, H., et al. MicroRNA deep sequencing reveals chamber-specific miR-208 family expression patterns in the human heart. Int J Cardiol 211 (2016), 43–48.
29. 29 Dirkx, E., Gladka, M.M., Philippen, L.E., et al. Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol 15 (2013), 1282–1293.
30. 30 Wahlquist, C., Jeong, D., Rojas-Muñoz, A., et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508 (2014), 531–535.
31. 31 Eulalio, A., Mano, M., Dal Ferro, M., et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492 (2012), 376–381.
32. 32 Boon, R.A., Iekushi, K., Lechner, S., et al. MicroRNA-34a regulates cardiac ageing and function. Nature 495 (2013), 107–110.
33. 33 Loyer, X., Potteaux, S., Vion, A.C., et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 114 (2014), 434–443.
34. 34 Bonauer, A., Carmona, G., Iwasaki, M., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324 (2009), 1710–1713.
35. 35 van Rooij, E., Sutherland, L.B., Thatcher, J.E., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105 (2008), 13027–13032.
36. 36 Abonnenc, M., Nabeebaccus, A.A., Mayr, U., et al. Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ Res 113 (2013), 1138–1147.
37. 37 Duisters, R.F., Tijsen, A.J., Schroen, B., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104 (2009), 170–178.
38. 38 Tijsen, A.J., van der Made, I., van den Hoogenhof, M.M., et al. The microRNA-15 family inhibits the TGFβ-pathway in the heart. Cardiovasc Res 104 (2014), 61–71.
39. 39 Castoldi, G., di Gioia, C.R.T., Bombardi, C., et al. MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol 227 (2012), 850–856.
40. 40 van Rooij, E., Sutherland, L.B., Liu, N., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103 (2006), 18255–18260.
41. 41 Thum, T., Gross, C., Fiedler, J., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456 (2008), 980–984.
42. 42 Roy, S., Khanna, S., Hussain, S.R.A., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 82 (2009), 21–29.
43. 43 Patrick, D.M., Montgomery, R.L., Qi, X., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 120 (2010), 3912–3916.
44. 44 Ji, R., Cheng, Y., Yue, J., et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res 100 (2007), 1579–1588.
45. 45 McDonald, R.A., Halliday, C.A., Miller, A.M., et al. Reducing in-stent restenosis: therapeutic manipulation of miRNA in vascular remodeling and inflammation. J Am Coll Cardiol 65 (2015), 2314–2327.
46. 46 Wang, D., Deuse, T., Stubbendorff, M., et al. Local microRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis. Arterioscler Thromb Vasc Biol 35 (2015), 1945–1953.
47. 47 Zampetaki, A., Attia, R., Mayr, U., et al. Role of miR-195 in aortic aneurysmal disease. Circ Res 115 (2014), 857–866.
48. 48 Maegdefessel, L., Azuma, J., Toh, R., et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest 122 (2012), 497–506.
49. 49 Ulrich, V., Rotllan, N., Araldi, E., et al. Chronic miR-29 antagonism promotes favorable plaque remodeling in atherosclerotic mice. EMBO Mol Med 8 (2016), 643–653.
50. 50 Cheng, Y., Liu, X., Yang, J., et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 105 (2009), 158–166.
51. 51 Cordes, K.R., Sheehy, N.T., White, M.P., et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460 (2009), 705–710.
52. 52 Lovren, F., Pan, Y., Quan, A., et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 126 (2012), S81–S90.
53. 53 Wang, S., Aurora, A.B., Johnson, B.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 15 (2008), 261–271.
54. 54 Schober, A., Nazari-Jahantigh, M., Wei, Y., et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 20 (2014), 368–376.
55. 55 Esau, C., Davis, S., Murray, S.F., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3 (2006), 87–98.
56. 56 Willeit, P., Skroblin, P., Kiechl, S., et al. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?. Eur Heart J, 2016 Apr 20 [E-pub ahead of print].
57. 57 Elmén, J., Lindow, M., Schütz, S., et al. LNA-mediated microRNA silencing in non-human primates. Nature 452 (2008), 896–899.
58. 58 Rayner, K.J., Suárez, Y., Dávalos, A., et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328 (2010), 1570–1573.
59. 59 Najafi-Shoushtari, S.H., Kristo, F., Li, Y., et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328 (2010), 1566–1569.
60. 60 Horie, T., Nishino, T., Baba, O., et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun, 4, 2013, 2883.
61. 61 Goedeke, L., Rotllan, N., Canfrán-Duque, A., et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med 21 (2015), 1280–1289.
62. 62 Mitchell, P.S., Parkin, R.K., Kroh, E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105 (2008), 10513–10518.
63. 63 Vickers, K.C., Palmisano, B.T., Shoucri, B.M., et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13 (2011), 423–433.
64. 64 Laffont, B., Corduan, A., Plé, H., et al. Activated platelets can deliver mRNA regulatory Ago2·microRNA complexes to endothelial cells via microparticles. Blood 122 (2013), 253–261.
65. 65 Gidlöf, O., van der Brug, M., Ohman, J., et al. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood 121 (2013), 3908–3917 S1-26.
66. 66 Tabet, F., Vickers, K.C., Cuesta Torres, L.F., et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun, 5, 2014, 3292.
67. 67 Shan, Z., Qin, S., Li, W., et al. An endocrine genetic signal between blood cells and vascular smooth muscle cells: role of microRNA-223 in smooth muscle function and atherogenesis. J Am Coll Cardiol 65 (2015), 2526–2537.
68. 68 Wang, G.-K., Zhu, J.-Q., Zhang, J.-T., et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31 (2010), 659–666.
69. 69 Widera, C., Gupta, S.K., Lorenzen, J.M., et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 51 (2011), 872–875.
70. 70 Roncarati, R., Viviani Anselmi, C., Losi, M.A., et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 63 (2014), 920–927.
71. 71 Karakas, M., Schulte, C., Appelbaum, S., et al. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study. Eur Heart J, 2016 Jun 29 [E-pub ahead of print].
72. 72 Bye, A., Røsjø, H., Nauman, J., et al. Circulating microRNAs predict future fatal myocardial infarction in healthy individuals – the HUNT study. J Mol Cell Cardiol 97 (2016), 162–168.
73. 73 Zampetaki, A., Willeit, P., Tilling, L., et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 60 (2012), 290–299.
74. 74 Schulte, C., Molz, S., Appelbaum, S., et al. miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease. PLoS One, 10, 2015, e0145930.
75. 75 Kaudewitz, D., Skroblin, P., Bender, L.H., et al. Association of microRNAs and YRNAs with platelet function. Circ Res 118 (2016), 420–432.
76. 76 Elgheznawy, A., Shi, L., Hu, J., et al. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res 117 (2015), 157–165.
77. 77 Willeit, P., Zampetaki, A., Dudek, K., et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 112 (2013), 595–600.
78. 78 Kondkar, A.A., Bray, M.S., Leal, S.M., et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 8 (2010), 369–378.
79. 79 Flierl, U., Nero, T.L., Lim, B., et al. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J Exp Med 212 (2015), 129–137.
80. 80 Anand, S., Majeti, B.K., Acevedo, L.M., et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 16 (2010), 909–914.